133 related articles for article (PubMed ID: 23624255)
21. [Transdermal properties of timolol and factors affecting its permeability in vitro].
Xu YZ; Xu HN
Yao Xue Xue Bao; 1992; 27(6):467-71. PubMed ID: 1442076
[TBL] [Abstract][Full Text] [Related]
22. Dual sorption model for the nonlinear percutaneous permeation kinetics of timolol.
Kubota K; Koyama E; Twizell EH
J Pharm Sci; 1993 Dec; 82(12):1205-8. PubMed ID: 8308696
[TBL] [Abstract][Full Text] [Related]
23. Predicting dermal absorption of gas-phase chemicals: transient model development, evaluation, and application.
Gong M; Zhang Y; Weschler CJ
Indoor Air; 2014 Jun; 24(3):292-306. PubMed ID: 24245588
[TBL] [Abstract][Full Text] [Related]
24. Enhancement of topical delivery of drugs via direct penetration by reducing blood flow rate in skin.
Higaki K; Nakayama K; Suyama T; Amnuaikit C; Ogawara K; Kimura T
Int J Pharm; 2005 Jan; 288(2):227-33. PubMed ID: 15620862
[TBL] [Abstract][Full Text] [Related]
25. Interfacial kinetics effects on transdermal drug delivery: a computer modeling.
Xing MM; Pan N; Zhong W; Hui X; Maibach HI
Skin Res Technol; 2008 May; 14(2):165-72. PubMed ID: 18412558
[TBL] [Abstract][Full Text] [Related]
26. A physiologically based pharmacokinetic model of organophosphate dermal absorption.
van der Merwe D; Brooks JD; Gehring R; Baynes RE; Monteiro-Riviere NA; Riviere JE
Toxicol Sci; 2006 Jan; 89(1):188-204. PubMed ID: 16221965
[TBL] [Abstract][Full Text] [Related]
27. Modeling Temperature-Dependent Dermal Absorption and Clearance for Transdermal and Topical Drug Applications.
LaCount TD; Zhang Q; Hao J; Ghosh P; Raney SG; Talattof A; Kasting GB; Li SK
AAPS J; 2020 May; 22(3):70. PubMed ID: 32390069
[TBL] [Abstract][Full Text] [Related]
28. Experimental verification of the mechanistic model for transdermal transport including iontophoresis.
Hirvonen J; Murtomäki L; Kontturi K
J Control Release; 1998 Dec; 56(1-3):169-74. PubMed ID: 9801440
[TBL] [Abstract][Full Text] [Related]
29. The transient dermal exposure II: post-exposure absorption and evaporation of volatile compounds.
Frasch HF; Bunge AL
J Pharm Sci; 2015 Apr; 104(4):1499-507. PubMed ID: 25611182
[TBL] [Abstract][Full Text] [Related]
30. Modeling the human skin barrier--towards a better understanding of dermal absorption.
Jepps OG; Dancik Y; Anissimov YG; Roberts MS
Adv Drug Deliv Rev; 2013 Feb; 65(2):152-68. PubMed ID: 22525516
[TBL] [Abstract][Full Text] [Related]
31. Numerical Investigation of Analytical Models of Drug Flux Through Microporated Skin.
Pavlov AM; Rzhevskiy AS; Anissimov YG
J Pharm Sci; 2019 Jan; 108(1):358-363. PubMed ID: 30439461
[TBL] [Abstract][Full Text] [Related]
32. Maximum flux versus transdermal delivery: comment on Farahmand and Maibach (2009).
Kissel JC; Bunge AL
Int J Pharm; 2010 Oct; 398(1-2):247-8. PubMed ID: 20600727
[No Abstract] [Full Text] [Related]
33. Distributed diffusion-clearance model for transient drug distribution within the skin.
Kretsos K; Kasting GB; Nitsche JM
J Pharm Sci; 2004 Nov; 93(11):2820-35. PubMed ID: 15389667
[TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamic effects of transdermal bupranolol and timolol in vivo: comparison of microemulsions and matrix patches as vehicle.
Kemken J; Ziegler A; Müller BW
Methods Find Exp Clin Pharmacol; 1991 Jun; 13(5):361-5. PubMed ID: 1921573
[TBL] [Abstract][Full Text] [Related]
35. A geometrical model of dermal capillary clearance.
Kretsos K; Kasting GB
Math Biosci; 2007 Aug; 208(2):430-53. PubMed ID: 17303187
[TBL] [Abstract][Full Text] [Related]
36. Transdermal skin delivery: predictions for humans from in vivo, ex vivo and animal models.
Godin B; Touitou E
Adv Drug Deliv Rev; 2007 Sep; 59(11):1152-61. PubMed ID: 17889400
[TBL] [Abstract][Full Text] [Related]
37. The use of mechanistically defined chemical mixtures (MDCM) to assess component effects on the percutaneous absorption and cutaneous disposition of topically exposed chemicals. I. Studies with parathion mixtures in isolated perfused porcine skin.
Qiao GL; Brooks JD; Baynes RE; Monteiro-Riviere NA; Williams PL; Riviere JE
Toxicol Appl Pharmacol; 1996 Dec; 141(2):473-86. PubMed ID: 8975772
[TBL] [Abstract][Full Text] [Related]
38. [The bioavailability of transdermal therapeutic system of timolol].
Ji XF; Ping QN; Liu GJ; Yu ST
Yao Xue Xue Bao; 1993; 28(8):609-13. PubMed ID: 8285070
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and characterization of captopril prodrugs for enhanced percutaneous absorption.
Moss GP; Gullick DR; Cox PA; Alexander C; Ingram MJ; Smart JD; Pugh WJ
J Pharm Pharmacol; 2006 Feb; 58(2):167-77. PubMed ID: 16451744
[TBL] [Abstract][Full Text] [Related]
40. Graphical process design tools for iontophoretic transdermal drug-delivery devices.
Simon L
Comput Methods Programs Biomed; 2012 Sep; 107(3):447-55. PubMed ID: 21345513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
